Medici Lipid Nanoparticle Technology potentially improves the delivery and therapeutic efficacy of various genetic drugs such as siRNA and ASO with less than MW of 20 kDa, and mRNA, samRNA (self-amplifying mRNA), and gRNA+Cas mRNA with more than MW of 100 kDa.

Biomaterial Platform Technology I : Medici Ionizable Lipid

Novel Medici Ionizable Lipid allows formulation of lipid nanoparticles with superior gene delivery efficacy and excellent stability over the current nanoparticle delivery system.

       * (Ref.) Lipid nanoparticle formulation : clinically approved delivery system of gene therapy through COVID-19 vaccine development

Biomaterial Platform Technology II : Medici Targeting Lipid

Novel Medici Targeting Lipid improves tissue-specific delivery of lipid nanoparticle containing  RNA/DNA drugs via targeting cell surface receptors or molecules highly expressed in specific tissues.

• Cancer-targeting lipid nanoparticle for cancer immunotherapy or vaccine
• Brain-targeting lipid nanoparticle for CNS genetic disease 

Evaluation for Formulated Genetic Drugs

For optimization of pharmaceutical formulation of genetic drugs, we assess its 1) physicochemical property, 2) in vitro/in vivo transfection efficacy, 3) stability for storage conditions, and 4) in vitro/in vivo toxicity.

Headquarter   A-2207, 184, Jungbu-daero, Giheung-gu, Yongin-si, Gyeonggi-do, 17095 Republic of Korea

Branch Office  A-13, 3rd Floor, 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28160 Republic of Korea

Tel ㅣ +82-31-895-6710     Fax ㅣ +82-70-8676-6706    Email ㅣ biz@medicibio.com

Copyright © MediciBIO Co.,LTD. All rights reserved.